Vimian Group AB stock analysis
Want to see SE:VIMIAN full AI Analyst Report?
Vimian Group AB (VIMIAN) Stock Price & Analysis
VIMIAN Stock Chart & Stats
- Day’s Range
- SEK 42.25 - SEK 42.75
- 52-Week Range
- SEK 24.18 - SEK 42.75
- Previous Close
- SEK 42.25
- Volume
- N/A
- Average Volume (3M)
- 316.25K
- Market Cap
- SEK 22.38B
- Enterprise Value
- SEK 21.72B
- Total Cash (Recent Filing)
- SEK 55.90M
- Total Debt (Recent Filing)
- SEK 281.69M
- Price to Earnings (P/E)
- 51.5
- Beta
- 0.51
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 0.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Vimian has built a sustained growth record across 2021–2025, with revenue still increasing in the trailing period. Continued expansion indicates broad demand for its veterinary products and services, supporting scale, market reach, and the potential for durable earnings growth.
Improving Profitability
The move from losses in 2022 to positive earnings and stronger operating profit demonstrates meaningful operating progress. If maintained, this improved profitability can strengthen internal funding, support reinvestment across veterinary businesses, and increase resilience over the next several quarters.
Cash Generation
Strong positive free cash flow and healthy conversion of earnings into cash provide tangible financial support for Vimian’s business model. This gives management greater flexibility to fund operations, invest in growth, and manage obligations without relying as heavily on external financing.
Bears Say
Gross Margin Compression
The notable trailing gross-margin decline signals cost or product-mix pressure beneath the company’s otherwise healthy operating performance. If this compression persists, it could reduce earnings quality, limit incremental profitability from revenue growth, and make future margin improvement more difficult.
Cash Flow Volatility
The negative operating and free cash flow recorded in 2023 shows that cash generation can fluctuate materially despite the subsequent recovery. Such volatility may complicate planning and capital allocation, while working-capital or timing effects could periodically weaken the cash support for reported earnings.
Modest Returns And Higher Debt
Although leverage remains moderate, rising absolute debt combined with still-modest returns indicates that capital is not yet producing especially strong shareholder outcomes. If profitability softens, higher debt could reduce financial flexibility and constrain the company’s ability to pursue growth or absorb weaker operating periods.
Vimian Group AB News
VIMIAN FAQ
What was Vimian Group AB’s price range in the past 12 months?
What is Vimian Group AB’s market cap?
When is Vimian Group AB’s upcoming earnings report date?
How were Vimian Group AB’s earnings last quarter?
Is Vimian Group AB overvalued?
Does Vimian Group AB pay dividends?
What is Vimian Group AB’s EPS estimate?
How many shares outstanding does Vimian Group AB have?
What happened to Vimian Group AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vimian Group AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Vimian Group AB
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Alireza Tajbakhsh
- Employees
- 1,300
- Website
- vimian.com
- Address
- Riddargatan 19, Stockholm, AB, 11457, SE
Vimian Group AB (VIMIAN) Earnings & Revenues
VIMIAN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:ALIF.BAddLife AB | ||
| SE:CEVICellaVision AB | ||
| SE:BACTI.BBactiguard Holding AB | ||
| SE:QLINEAQ-linea AB | ||
| SE:DVYSRDevyser Diagnostics AB |











